Mismatch repair protein expression in patients with stage II and III sporadic colorectal cancer

Zhao,Lihua

doi:10.3892/ol.2018.8337

Mismatch repair protein expression in patients with stage II and III sporadic colorectal cancer

Authors:
- Lihua Zhao
View Affiliations

Affiliations: Department of Pathology, Beijing Civil Aviation Hospital, Beijing 100123, P.R. China
Published online on: March 23, 2018 https://doi.org/10.3892/ol.2018.8337
Pages: 8053-8061

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) may be classified according to the level of microsatellite instability exhibited by the tumor. The malignant transformation of normal colonic mucosae to carcinomas may be accelerated by the loss or inactivation of DNA mismatch repair (MMR) genes. The present study examined the expression of certain MMR proteins [namely, MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), MutS homolog 6 (MSH6) and PMS1 homolog 2 (PMS2)] in patients with stage II and III sporadic CRC. The association between the expression of these proteins, and the clinicopathological characteristics of patients with CRC and their tumors, was investigated. MMR protein expression was examined using immunohistochemistry. MLH1, MSH2, MSH6 and PMS2 protein expression was detected in 78.4% (120/153), 75.2% (115/153), 44.4% (68/153) and 79.7% (122/153) of stage II and III sporadic CRCs, respectively. Additionally, the expression of MLH1 and MSH6 was revealed to be significantly higher in stage III tumors when compared with stage II tumors (P<0.05). MLH1 and MSH6 negative tumors were larger, poorly differentiated and exhibited extraserosal invasion with infrequent lymph node metastasis (P<0.05). Patients with defects in MLH2 and PMS2 also had large tumors that exhibited extraserosal invasion and infrequent lymph node metastasis (P<0.05). No statistically significant associations were observed between MLH1, MSH2, MSH6 or PMS2 protein expression and patient age, sex, tumor localization or angiolymphatic invasion status (P>0.05). From the present study, it was concluded that MMR protein expression status evaluation may increase the efficiency of MMR testing and be useful in improving the individualized approach to patient monitoring and therapy.

View Figures

View References

1	Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MW: Colorectal cancer. Lancet. 365:153–165. 2005. View Article : Google Scholar : PubMed/NCBI
2	Black RJ, Bray F, Ferlay J and Parkin DM: Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 33:1075–1107. 1997. View Article : Google Scholar : PubMed/NCBI
3	Mundade R, Imperiale TF, Prabhu L, Loehrer PJ and Lu T: Genetic pathways, prevention, and treatment of sporadic colorectal cancer. Oncoscience. 1:400–406. 2014. View Article : Google Scholar : PubMed/NCBI
4	Lee JH, Cragun D, Thompson Z, Coppola D, Nicosia SV, Akbari M, Zhang S, McLaughlin J, Narod S, Schildkraut J, et al: Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer. Genet Test Mol Biomarkers. 18:229–235. 2014. View Article : Google Scholar : PubMed/NCBI
5	Haydon AM and Jass JR: Emerging pathways in colorectal-cancer development. Lancet Oncol. 3:83–88. 2002. View Article : Google Scholar : PubMed/NCBI
6	Jascur T and Boland CR: Structure and function of the components of the human DNA mismatch repair system. Int J Cancer. 119:2030–2035. 2006. View Article : Google Scholar : PubMed/NCBI
7	Pawlik TM, Raut CP and Rodriguez-Bigas MA: Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers. 20:199–206. 2004. View Article : Google Scholar : PubMed/NCBI
8	Wheeler JM, Bodmer WF and Mortensen NJ: DNA mismatch repair genes and colorectal cancer. Gut. 47:148–153. 2000. View Article : Google Scholar : PubMed/NCBI
9	Yoon YS, Yu CS, Kim TW, Kim JH, Jang SJ, Cho DH, Roh SA and Kim JC: Mismatch repair status in sporadic colorectal cancer: Immunohistochemistry and microsatellite instability analyses. J Gastroenterol Hepatol. 26:1733–1739. 2011. View Article : Google Scholar : PubMed/NCBI
10	Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen GM, Walsh MD, Leggett BA, et al: Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 20:1043–1048. 2002. View Article : Google Scholar : PubMed/NCBI
11	Lanza G, Gafà R, Maestri I, Santini A, Matteuzzi M and Cavazzini L: Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol. 15:741–749. 2002. View Article : Google Scholar : PubMed/NCBI
12	Smith NJ, Bees N, Barbachano Y, Norman AR, Swift RI and Brown G: Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: Implications for clinical trials. Br J Cancer. 96:1030–1036. 2007. View Article : Google Scholar : PubMed/NCBI
13	Boland CR and Goel A: Microsatellite instability in colorectal cancer. Gastroenterology. 138:2073–2087. 2010. View Article : Google Scholar : PubMed/NCBI
14	Iacopetta B, Grieu F and Amanuel B: Microsatellite instability in colorectal cancer. Asia Pac J Clin Oncol. 6:260–269. 2010. View Article : Google Scholar : PubMed/NCBI
15	Sameer AS, Nissar S and Fatima K: Mismatch repair pathway: Molecules, functions, and role in colorectal carcinogenesis. Eur J Cancer Prev. 23:246–257. 2014. View Article : Google Scholar : PubMed/NCBI
16	Michailidi C, Papavassiliou AG and Troungos C: DNA repair mechanisms in colorectal carcinogenesis. Curr Mol Med. 12:237–246. 2012. View Article : Google Scholar : PubMed/NCBI
17	Raut CP, Pawlik TM and Rodriguez-Bigas MA: Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res. 568:275–282. 2004. View Article : Google Scholar : PubMed/NCBI
18	Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN and Srivastava S: A National cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58:5248–5257. 1998.PubMed/NCBI
19	Bao F, Panarelli NC, Rennert H, Sherr DL and Yantiss RK: Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma. Am J Surg Pathol. 34:1798–1804. 2010. View Article : Google Scholar : PubMed/NCBI
20	Kim JC, Cho YK, Roh SA, Yu CS, Gong G, Jang SJ, Kim SY and Kim YS: Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors. Cancer Sci. 99:1348–1354. 2008. View Article : Google Scholar : PubMed/NCBI
21	Sinicrope F, Foster NR, Sargent DJ, Thibodeau SN, Smyrk TC and O'Connell MJ: North Central Cancer Treatment Group: Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer. 116:1691–1698. 2010. View Article : Google Scholar : PubMed/NCBI
22	Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Balaguer F, Sempere L, Xicola RM, Bujanda L, et al: The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer. 45:365–373. 2009. View Article : Google Scholar : PubMed/NCBI